期刊
CELLS
卷 10, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cells10061417
关键词
lung transplantation; ischemic reperfusion injury; pulmonary inflammation; primary graft dysfunction; ex-situ lung perfusion
类别
Lung transplantation is the gold standard treatment for end-stage lung disease, but waitlist mortality is high due to a shortage of suitable donor lungs. Lung ischemic reperfusion injury (LIRI) can compromise organ quality and lead to primary graft dysfunction (PGD). Research into preservation strategies to decrease the risk of LIRI and PGD is crucial for improving patient outcomes.
Lung transplantation (LTx) is the gold standard treatment for end-stage lung disease; however, waitlist mortality remains high due to a shortage of suitable donor lungs. Organ quality can be compromised by lung ischemic reperfusion injury (LIRI). LIRI causes pulmonary endothelial inflammation and may lead to primary graft dysfunction (PGD). PGD is a significant cause of morbidity and mortality post-LTx. Research into preservation strategies that decrease the risk of LIRI and PGD is needed, and ex-situ lung perfusion (ESLP) is the foremost technological advancement in this field. This review addresses three major topics in the field of LTx: first, we review the clinical manifestation of LIRI post-LTx; second, we discuss the pathophysiology of LIRI that leads to pulmonary endothelial inflammation and PGD; and third, we present the role of ESLP as a therapeutic vehicle to mitigate this physiologic insult, increase the rates of donor organ utilization, and improve patient outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据